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DIETARY SODIUM AND BLOOD PRESSURE CHANGES
IN HEMODIALYSIS PATIENTS UNDERGOING A
LIBERALIZED RENAL DIET INTERVENTION

Lauren Eve Chan
51 Pages
Objective: Investigate the impacts of individual liberalized renal diet counseling in conjunction
with a volume reduction hemodialysis (HD) protocol.
Design & Methods: Twenty-three maintenance HD patients (age = 55.7 ± 13.3y, 47.8% female),
consented and completed this pilot intervention. Across the six-month intervention, participants
received thrice weekly dietary counseling about a liberalized renal diet. Liberalized renal dietary
guidelines promoted a low sodium diet with greater unprocessed food consumption, decreasing
foods eaten outside the home, and increased food label reading. Participant HD sessions were
conducted per a volume reduction protocol, gradually decreasing patient post-dialysis weight by
removing an additional 200-300 mL/session. Preliminary outcome measures included dietary
intake and knowledge, blood pressure (BP), anti-hypertensive medication use, and volume
overload (VO).
Results: From baseline (BL) to six months (6m), total sodium intake numerically decreased (BL
2886 ± 1570.6 vs 6m 2315 ± 1095 mg, p=0.13), systolic BP (BL 160 ± 25 vs. 6m 156 ± 23
mmHg, p=0.56) and diastolic BP (BL 81 ± 20 vs 6m 79 ± 15 mmHg, p= 0.73) showed no
significant changes, but total number of anti-hypertensive medications prescribed to patients (BL
3 ± 1 vs 6m 2 ± 1 medications) were significantly reduced (p=0.003). Additionally, significant
improvements were noted in VO (BL 3.6L ± 3.9L vs 6m 2.5L ± 3.5L, p=0.01).

Conclusion: Liberalized renal diet education had little effect on sodium intake, likely
contributing only minimally to BP control. Volume reduction protocol with gradual reduction of
post dialysis weight resulted in significantly decreased VO, and maintenance of BP with
coinciding decreases in anti-hypertensive medication usage. Our findings document intervention
opportunities to improve BP and decrease medication usage for HD patients.

KEYWORDS: hemodialysis, liberalized renal diet, volume reduction, blood pressure, sodium
reduction, anti-hypertensive medication
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CHAPTER I: MANUSCRIPT
INTRODUCTION
Prevalence of end stage renal disease (ESRD) is increasing in the United States (US),
with approximately 110,000 new cases each year.1 Patients with ESRD typically have less than
15% function of their kidneys, a glomerular filtration rate (GFR) of <15.2 ESRD patients require
either peritoneal dialysis or hemodialysis (HD) or other blood filtration treatments to supplement
fluid and metabolic waste removal, with HD being the most common selection.2
HD treatments are particularly important to remove minerals such as sodium, potassium,
and phosphorus from the blood. These dietary minerals greatly impact fluid balance and can alter
blood pressure (BP) levels if their concentrations are irregular.5 Increased levels of these
minerals, sodium in particular, alter BP when concentrations are greater than normal causing
increased fluid retention.6 Sodium consumption is also directly tied to thirst, and with additional
sodium intake a patient will experience a strong physiological thirst sensation leading them to
drink more fluid.6 By introducing more fluid to the system, the patient will increase their body
fluid volume.6 Expanded body fluid, and in turn blood volume, can increase BP, leading many
patients to develop or exacerbate pre-existing hypertension (HTN) or other cardiovascular (CV)
risks such as aortic stiffness.7
Currently, upwards of 80-90% of HD patients experience HTN.8 In an investigation with
greater than 30,000 individual HD patients, large gains of body fluid between dialysis sessions,
defined as > 4.0 kg, were correlated with higher risk of death over the following two years.9 With
cardiovascular disease (CVD) being the main cause of death among ESRD patients,
encompassing 41% of patient deaths,10 BP management strategies are critical for this population.
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In the US, treatment for HD patients include both lifestyle and pharmaceutical approaches in
addition to regular dialysis treatments to maintain healthy BP.3,4
For improved BP and health management, HD patients are often counseled to follow the
traditional renal diet to decrease their dietary mineral intake in an effort to manage their
interdialytic blood mineral concentrations. Restricted foods include dairy, nuts, whole grains,
fruits, and vegetables, making it a complicated and challenging diet to follow.11 With
recommendations to limit traditionally heart healthy foods, HD patients may be at risk of
consuming a pro-atherogenic diet that is low in fiber and micronutrients.11,12 In addition, HD
patients often experience multiple barriers for dietary change that can vary from struggles
learning to utilize new food items13, to the desire for more individualized dietary guidance.14
Furthermore, most hypertensive American HD patients are prescribed anti-hypertensive
medications as the primary treatment to decrease BP.15 Although anti-hypertensive BP
medications are commonly used, their effectiveness in this population is questionable. For
significant BP reduction, some HD patients need upwards of four medications to alter their
BP.15,16,17 Additionally, medications are expensive to purchase, challenging to monitor and
maintain, and can have other unwanted side effects including an increased risk for interdialytic
hypotension.5,15,18 In efforts to significantly reduce and maintain appropriate BP levels, patients
may need alternative treatments to medications.
Controlling dietary sodium intake is an important component to managing BP. Currently
recognized as part of the traditional renal diet, limiting sodium intake to less than 2,000
milligrams per day can reduce fluid retention and BP in HD patients.6,19 Although sodium
recommendations are typically given to HD patients, poor dietary sodium adherence is common.
Poor adherence may be related to various barriers for dietary changes, including how confusing
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and overwhelming the traditional renal diet is.11,13,14 Recent efforts to simplify the renal diet are
being considered to help HD patients focus on sodium reduction to decrease the onset or
progression of HTN. Additionally, a more liberalized diet may allow for patients to have greater
food selection, more micronutrients, and increased fiber in their diet, a concern for many HD
patients.11,20
In addition to dietary adaptations, HTN and volume overload (VO) may be altered
through volume reduction protocol with the removal of an additional 200-300 mL of fluid per
HD session. A patient’s dry weight is often an estimation made by a nephrologist, rather than an
objective measurement of the patient’s edema free body weight, and thus only dialyzing to the
dry weight may leave excess fluid on the body and maintain an elevated BP.9,21 By seeking to
remove a small amount of additional fluid during each dialysis session, the patient may come
closer to their actual edema free body weight and gradually reduce their BP.21
By reducing post dialysis weight each session and using dietary interventions such as the
liberalized renal diet, patients may see a reduction in BP alongside a decreased need for BP
medications. In turn, this may result in better CVD outcomes and lower mortality risk for HD
patients.
Following a six-month intervention with education on a liberalized renal diet and the use
of volume reduction protocol, we hypothesized patients in this pilot study would experience a
decline in total daily sodium intake (mg), decrease in systolic and diastolic BP (mmHg), and a
reduction in the number of anti-hypertensive medications used.
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METHODOLOGY
Design and Subjects
This study served the purpose of documenting how low sodium focused, liberalized renal
nutrition recommendations can affect dietary sodium intake, BP, anti-hypertensive medication,
and prevalence of VO in U.S. HD patients. This is a retrospective analysis of a prospective,
multi-center, intervention conducted in Central Illinois.
Purposive, convenience sampling was used to identify 32 HD patients from participating
HD clinics in Peoria and Champaign, Illinois. Inclusion criteria was HD treatment for ESRD,
and the exclusion criteria was decompensated heart failure as classified by a physician. Patients
gave written consent for participation and signed health information release forms prior to
starting, allowing for research staff to access medical information including height, weight,
medications, HD and comorbidity history, and other laboratory reports. Following consent, all
patients were evaluated by a registered dietitian and a nephrologist for safety clearance to
participate. The University of Illinois and Illinois State University Institutional Review Boards
approved this protocol. All procedures were in accordance of the Declaration of Helsinki.
Data Collection Periods
The two data collection periods included the week prior to a patient starting the
intervention, and the week following the conclusion of the six-month intervention treatment.
During each week-long collection period, patients underwent a series of measures at their regular
HD sessions including dietary intake, nutrition knowledge, BP, medication use, VO, and other
related values. Collection was conducted by a trained member of the research staff or a HD
technician or nurse.
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General Measures
Data on demographic features were collected (age, gender, smoker), alongside clinical
measures (height, post-dialysis weight, interdialytic weight gain (IDWG), presence of diabetes,
HD vintage in years). Continuous variable measures were taken in triplicate and averaged where
appropriate.
Body Fluid and Volume Overload
Evaluation of body fluid and fluid overload experienced by a patient was conducted by a
trained researcher using a portable bioimpedance spectroscopy (BIS) machine (ImpediMed
SFB7). Patients underwent this non-invasive procedure prior to and following HD treatment
once during each collection period. For this measure, the BIS system utilized a single channel of
tetra polar BIS to scan electrical frequencies for patient body composition estimation. Each
patient was seated and had two electrode leads each placed on their non-access hand and foot on
the same side of the body. The two hand leads were placed on the wrist next to the ulnar head,
and on the dorsal surface of the hand. The foot leads were placed on the dorsal surface of the foot
on the ankle at the level of medial and lateral malleoli, and on the dorsal surface of the foot. This
low frequency BIS system assessed patient’s extracellular fluid (ECF), intracellular fluid, and
total body water (TBW). Based on these outputs, the patient’s percent and liters of VO could be
calculated.22
Blood Pressure and Medication Use
BP measures were taken by an HD technician or nurse during every HD session the
patient attended. For this study, measures of pre-HD BP were recorded during each collection
period, each on a separate HD treatment day. Prior to the start of HD treatment, patients had their
BP measured through a sphygmomanometer attached to an HD machine. Patients were asked to
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sit resting for at least five minutes prior to testing BP on their non-dialysis port arm. Measures of
systolic and diastolic BP were documented and the treatment commenced. Throughout the
entirety of the study, patients had their systolic and diastolic pre-HD BP documented six times,
three pre-intervention and three post- intervention measurements. Following both collection
periods, systolic and diastolic BP were averaged to interpret the mean pre-intervention BP and
mean post-intervention BP.
Patients self-reported how many anti-hypertensive medications they were currently
prescribed from a physician and taking on a regular basis to help control elevated BP levels and
HTN. To ensure accuracy, patients brought all current prescriptions to an HD session and
research staff documented how many were for BP reduction. The number of anti-hypertensive
medications a patient was prescribed was recorded once during each collection period.
Nutrition Knowledge
Patients were evaluated on their knowledge of nutrition information about protein,
sodium, and phosphorus prior to and following the intervention period. Questionnaires were
based on label reading, nutrient content of common foods, and general knowledge related to
nutrition.23,24,25 Each patient completed this questionnaire one time during each collection period.
Scores were calculated for percent correctness on each questionnaire.
Dietary Intake
Each patient underwent three 24-hour dietary recalls during each collection period for
three separate days of food consumption. Recalls were conducted by a trained researcher based
on the USDA 5-pass method with steps for documenting foods eaten, probing for forgotten foods
or beverages, prompting for portion sizes, questioning for brand names, and final confirmation of
the day’s intake (Appendix A). This multi-pass approach collects a patient’s single day dietary
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intake of food, beverages, vitamins, minerals, and supplements. The three recalls were evaluated
on a dialysis weekday, non-dialysis weekday, and a non-dialysis weekend day. Each recall
session lasted approximately 15 minutes. Dietary recalls were conducted verbally and recorded
by hand then later transferred into the Nutrition Data System for Research (NDSR) software for
analysis of micronutrient and macronutrient intake. Within the scope of this investigation, a total
of six 24-hour dietary recalls were completed, three pre-intervention, and three post-intervention.
After evaluating through NDSR, patient’s dietary intake was consolidated to average preintervention intake and average post-intervention intake and used for analysis.
Intervention
Liberalized Renal Diet Education
Patients were counseled individually on the liberalized renal diet by a researcher twice
per week for six months. Counseling sessions were held during a patient’s regular HD sessions
and each lasted approximately 15 minutes. Weekly counseling included individualized
education, goal setting, and patient support focused on a liberalized renal diet and reducing
patient sodium intake. Patients discussed their previous week’s meals and adherence to the
guidelines of a liberalized renal diet (Appendix B). Interviews served to continue discussion and
education about the diet, and analyze the patient’s progress towards achieving their personal
goals. Dietary goal setting was conducted through a specific, measurable, attainable, relevant,
and time-related (SMART) goal model, a validated and reliable method of developing clinically
based goals26 (Appendix C).
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Volume Reduction Protocol
In combination with reducing an individual’s dietary sodium intake and BP medication
use, the objective of the volume reduction protocol was to slowly decrease participants’ postdialysis weight, thereby decreasing their degree of total VO and ultimately reducing their
estimated dry weight (EDW). EDW was reduced until either the patient’s BP normalized (below
140/90 mmHg) or the patient consistently experienced hypotensive events including cramping,
headaches, or nausea during their HD treatments. All volume reduction efforts were conducted
under the supervision of a nephrologist. Nurses and technicians were instructed to decrease the
post-dialysis weight by 200-300 grams per dialysis session, until pre-dialysis BP measures
normalized to 140/90 mmHg or less in the absence of antihypertensive medications. HD staff
were discouraged from administering saline to mitigate complications or discomfort, as were
patients from requesting saline or a modification of their prescription.
Statistical Analysis
Statistical analyses were conducted using the Statistical Package for Social Sciences
(SPSS) version 22 (Chicago, IL, USA). Continuous variables were reported as mean and
standard deviation. Comparison of pre-and post-intervention measurements was conducted using
the paired t-test. Categorical data was analyzed using the chi-squared test and are reported in
frequencies and percentages. A p-value <0.05 was accepted as significant for all statistical
analyses.
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RESULTS
Participant Demographics
Individuals with ESRD receiving maintenance HD at the Peoria, IL and Champaign, IL
Fresenius dialysis clinics were invited to participate in the study. All 32 patients consented to
participate, but nine individuals elected to discontinue the study protocol before completion,
reducing the number of participants to 23. Participants withdrew for various reasons including:
relocation, transplant surgery, extensive health concerns, and imprisonment. Within the 23
participants, 12 were males and 11 were females between the ages of 22-81 years old (mean 55.7
± 13.3 years), of mixed ethnicity (Caucasian, African American, Hispanic) (Table 1).
Body Fluid and Volume Overload
Results from BIS allow for comparison of fluid volume and VO changes related to the
intervention. Significant changes were seen for ECF decreasing from 21.7 (+ 5.8) to 20.5 (+ 4.5)
L (p=0.004) (Figure 1) and for VO values as well. VO in liters reduced from 3.6 (+ 3.9) to 2.5 (+
3.5) L (p=0.01) (Figure 1), a decrease from 15 (+ 15) to 11 (+ 17) % (p=0.04) (Figure 2). TBW
did not change with intervention (45.8 (+ 10.8) to 44.3 (+ 8.8) L (p=0.10)) (Table 2).
Weight
Weight measures for participants were compared following the intervention period,
including average weight and average IDWG. A significant reduction was seen in patient weight
on average from 93.6 (+ 24.4) to 91.8 (+ 22.7) kg, (p=0.02), although the drop in average IDWG
was negligible at 3.2 (+ 1.1) versus 3.0 (+ 1.0) kg, (p = 0.40) (Table 1).
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Blood Pressure and Medication Use
Mean pre-dialysis BP measures did not differ for both average systolic and diastolic
values following the intervention. The non-significant alteration in systolic BP valued at 160 (+
25) and 156 (+ 23) mmHg (p=0.56) for pre- and post- measurements, respectively, while
diastolic BP was 81 (+ 20) and 79 (+ 15) mmHg (p= 0.73). Although pre-dialysis BP
measurements did not change significantly, anti-hypertensive medication decreased significantly
after the 6-month intervention period. On average, anti-hypertensive prescriptions reduced
significantly from 3 (+ 1) to 2 (+ 1) medications per participant (p=0.003) (Table 3).
Post Intervention Dietary Intake and Knowledge
Mean dietary sodium intake, analyzed through 24-hour dietary recalls, decreased nonsignificantly following the intervention with measurements of 2,886 (+ 1,570) and 2,315 (+
1,095) mg at pre- and post-intervention, respectively (p = 0.125). Additionally, protein
consumption did not differ before and after the intervention period (61 + 30 before and 56 + 21 g
protein after, p=0.60). No significant alterations were seen in energy intake per day before and
after intervention (1,588 +1,061kilocalories (kcals) vs. 1,366 + 455 kcals, (p= 0.38)) (Table 4).
Nutrition knowledge levels, measured through the percentage correct of questionnaire
responses, reflect progression following the intervention. Significant improvement was seen for
average phosphorus knowledge questionnaire scores from 66 (+ 15) to 74 (+14) %, (p= 0.04).
Although non-significant, progression in sodium and protein knowledge was also seen. Average
sodium scores increased from 68 (+ 27) to 76 (+30) % (p=0.06) following the intervention, and
numerical changes in average protein knowledge scores ranged from 81 (+ 18) to 84 (+ 14) %,
(p=0.25). (Table 5).
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DISCUSSION
The main objectives of this study were to explore the impacts of a liberalized renal diet
with volume reduction on HD patients. Areas of measurement included demographics, dietary
intake, nutrition knowledge, BP, anti-hypertensive medication use, and body fluid levels. The
primary new findings of this preliminary intervention study are that individuals receiving a
liberalized renal diet education alongside volume reduction HD protocol had 1) reductions in
VO; 2) decreases in average weight; 3) significant reduction in BP medication use with marginal
differences in BP; 4) improvement in dietary phosphorus knowledge with slight increases in
dietary sodium and protein comprehension; and 5) minimal variance in dietary sodium, protein,
and calorie intake.
Body fluid levels deciphered through BIS were noteworthy on multiple fronts with
decreases in total VO and ECF. Significant reductions in VO and body fluid retention can likely
be attributed to the aggressive fluid removal that took place during volume reduction HD
protocol. By continuously lowering a patient’s target dry weight by 200-300 grams per session,
their body fluid levels were predicted to gradually decrease. This decrease in body fluid may
then lead to reduced CV workload, decreased BP, and less edema.21,27 Reduction in a patient’s
dry weight is beneficial as their dry-weight is often determined only by clinical judgement rather
than an objective measure of actual patient weight without edema.9 A similar study described
their fluid removal process as “intensified” and used maximal ultrafiltration (UF) on their
patients until their BP was below 140/90 mmHg without medication usage,21 with supplemental
HD session as needed. Similar to our findings, the intensified UF resulted in decreased
extracellular fluid and blood volume levels, likely benefiting CV health through reduced blood
volume and stress on the CV system. Coinciding with the overall decreases in body fluid
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overload, patients also experienced a significant decrease in average weight following the
intervention. As changes in weight for HD patients are often related to changes in body hydration
status, this finding is likely correlated with the reduced VO status.9
A sodium restricted diet is an integral component to success with this modified UF
protocol as it should decrease patient thirst and overall fluid intake. Ozkahya et al.,21 also
implemented a sodium restricted diet, and reported significant reductions in BP outcomes with
little medication usage. Patients in the Ozkahya et al.,21 study had high adherence rates to the low
sodium diet protocol, which was contrary to the findings within our study. Indeed, other
investigations reported reductions in sodium intake associated with decreased fluid retention,
thirst, and BP.6,21,28
With non-significant reductions in sodium intake, contrary to the hypothesized outcome,
the reported body fluid reductions are likely unrelated to decreases in sodium intake. Although
the dietary protocol may not have greatly impacted body fluid levels, the overall decrease in fluid
overload may in turn reduce patient mortality rates22 and could improve the ability to decipher a
patient’s actual EDW.29
As decreases in body fluid overload are related to BP reduction within HD patients9,28, we
anticipated a resulting decrease in BP for our patients alongside their reduced VO. Contrary to
expectation, our participants did not have a significant reduction in systolic nor diastolic BP. The
negligible change seen in BP levels may have been due to poor adherence to the low-sodium
dietary protocol, as other studies with persistent UF and low sodium diets found success gaining
control of BP levels following similar interventions.16,21 Due to the minimal sodium restriction
seen, we hypothesized that our participants did not realize the full extent of possible HTN
attenuation. With substantial reductions in sodium, our participants could have experienced
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better VO control, favorable improvement in BP control, and greater preservation of their
systolic and diastolic functions with little to no reliance on BP medications.7
Although BP adaptations were not prominent, reduction in overall VO did seem to have a
positive effect on anti-hypertensive medication uses. On average, our participants significantly
decreased their medication usage as hypothesized without seeing a consequent rise in BP,
indicating some improvement in BP control. Though BP levels were stagnant, diminished patient
dependency on medications may help reduce other concerns such as cardiac stress and mortality
rates, as well as producing fewer cases of intradialytic hypotension, with decreased severity of
left ventricular dysfunction.15,16 Our patient’s decrease in body fluid overload likely lowered their
BP medication needs, while avoiding a subsequent spike in BP. Although there was no
significant change in BP, it can be hypothesized that with greater low sodium diet adherence,
patients on a similar UF protocol would experience a decrease in both anti-hypertensive
medication usage and BP.
Renal dietitians are the primary providers of nutrition education for HD patients.14 In
previous interventions, patients received dietary education materials to foster adherence to a
therapeutic diet.30 In our intervention, we attempted to give customized nutrition education to
patients through individual counseling sessions. With additional knowledge of nutrition
concepts, we predicted that individuals in this intervention would adapt their dietary intake based
on guidelines provided through education modules. Post-intervention, participants displayed
significantly higher phosphorus knowledge scores, with some improvements in sodium and
protein knowledge.
With the nutrition knowledge progress, the outcomes for dietary sodium, protein, and
calorie intake did not correlate with our prediction. Individuals experienced non-significant
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decreases in general across these dietary intake categories, yet only sodium reduction was
specifically targeted in participant counseling sessions. As sodium reduction was a primary
marker of patient dietary adherence, the non-significant reduction highlights a lack of
compliance from participants that may have been instigated by barriers for dietary change.
Difficulty adhering to a reduced sodium diet is not unheard of, as previous investigations have
indicated multiple barriers HD patients face when limiting sodium intake. Challenges for
reducing sodium intake include limited availability of low sodium foods, poor intrinsic
motivation for dietary change, and limited understanding of dietary change and associated health
outcomes.13,33
One prominent factor making sodium reduction so difficult is the lack of social support
patients get from their family and friends.13,31 Patients often feel uncomfortable discussing their
special dietary needs with their loved ones, and their family is not often involved with education
sessions, limiting the family’s ability to assist or participate in the dietary changes. Consideration
for the barriers to understanding and achieving a low sodium diet may be necessary to clarify the
importance of the diet and encourage inclusion of loved ones in this lifestyle change.
Additionally, sodium is a component of many food items sold commercially and avoiding
high salt foods can be almost impossible. Both patients and professionals agreed that avoiding
sodium in pre-made foods is hard to do and time consuming.13,32 Furthermore, with the increasing
use of sodium in foods for flavor and preservation32, many individuals have strong taste
preferences for high sodium foods and they often do not find low sodium foods palatable.
Although increases in knowledge may be associated with improved therapeutic diet adherence34,
this may be a weak relationship compared to other contributing factors of dietary compliance.35
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Neither protein nor kilocalories were recommended for reduction within the liberalized
renal diet, thus patient’s average numerical decrease in energy and protein intake was
undesirable. Anorexia is a common barrier seen within the HD population and may have
prompted the slight decrease in patient consumption.36 The minimal decreases may have also
been related to the sodium restricted diet approach, as previous research indicates patients may
decrease total energy intake to minimize sodium intake.11
Intake documentation utilized 24-hour dietary recalls that require an administrator to
collect patient self- reported data, which allows low literacy patients to still participate. Dietary
recall periods following closely after meals also reduces the risk for inaccuracies.37 Nevertheless,
patient’s self-report of intake presents opportunity for inaccuracy due to over reporting of
healthy behaviors, under reporting of unhealthy behaviors, changes in behaviors due to the
research project, inaccuracies based on a participant’s ability to report correct information, or
other unpredictable errors.38 Alternative methods for monitoring intake exist, but also have
weaknesses such as generalizing patient food intake and lack of food choices presented in the
recall.37 Although the 24-hour dietary recall was the best choice for our intervention, the
unpredictable level of error from patient self-reporting may have skewed the dietary intake
results. Finally, our participants did spend time with our nutrition research staff during their HD
treatments, but they did not spend additional time with their clinic’s renal registered dietitian
(RD). Increasing time spent with their regular renal RD may have produced different dietary
outcomes.
Although participants did not achieve all the predicted outcomes, this study design did
result in various improvements such as a decrease in anti-hypertensive medication use and
significant reductions in VO. Some of the study’s strengths included a dietary education
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approach based on individual goals meant to improve specific patient outcomes, and the gradual
adaptation of an individual’s estimated post dialysis weight through volume reducing UF. Our
volume reduction process allowed for continuous decreases in each patient’s post dialysis weight
and re-evaluation of a patient’s EDW, which likely impacted the positive decline in VO.
Alongside those strengths, areas for improvement and future research opportunities were
also highlighted including: identifying and targeting personal barriers for dietary success,
pursuing sustainable and self-motivated dietary goals, seeking to build an individual’s support
systems for greater dietary adherence, and eliciting greater support for this intervention from HD
clinic staff.
The most prominent limitation of this study included a lack of staff participation and
involvement within the selected HD clinics. Despite attempts to provide information to staff
regarding the study, the intervention remained an effort conducted by outside research personnel.
The regular dialysis staff lacked incentive for participation and were already busy. In order for
this intervention to be truly effective, all HD care providers must be motivated to continually
display a united message or risk blunted study outcomes. In future interventions, adequate
training programs and communication techniques should be implemented. Attention to HD staff
training may improve support and decrease confusion for all dietary and UF protocols and
encourage all staff to be involved and accountable for patient care.
Although this study was a positive addition to the body of work surrounding a liberalized
renal diet and volume reduction protocol, further research is needed in this field to ensure HD
patients the highest care and quality of life. As many patients experience obstacles keeping them
from making lifestyle changes, finding greater understanding of each individual’s barriers to
change may be beneficial for future studies. By identifying and catering a patient’s treatments to
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their needs, a patient may see increased dietary adherence and improved health outcomes. Future
interventions may also consider methods of nutrition education outside of the dialysis clinic.
Presuming internet accessibility, exploring online instruction or video chats may allow for
inclusion of family and friends in education sessions as well as allowing for alternate locations
and learning resources. Removing lessons from the dialysis center may encourage greater patient
comprehension and adherence, while offering the chance to build a patient’s support system, a
common concern for HD patients.14,33 Further studies should also consider additional lesson
planning or training modules to educate all dialysis center and research staff on communication
and appropriate research protocols. By creating open dialogue between the research and dialysis
center staff, the ultimate goal of providing excellent patient care can better be achieved in
addition to providing adequate research outcomes.
CONCLUSION
Patients experiencing liberalized renal diet education as well as volume reduction HD
protocol decreased their average anti-hypertensive medication usage, and significantly reduced
their VO. Although systolic and diastolic BP were unaltered contrary to the hypothesis, the
stability of BP with a coinciding decrease in anti-hypertensive medication usage supports the
consideration of lifestyle and UF changes as opposed to pharmaceutical approaches. This study
provides preliminary evidence for future investigations aimed at lowering HD patient BP through
sodium reduction and UF changes rather than prescription medication use.
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CHAPTER II: LITERATURE REVIEW
INTRODUCTION
End Stage Renal Disease (ESRD) has become an increasing public health concern, with
over 110,000 new cases diagnosed in the United States (US) each year.1 ESRD refers to stage V
chronic kidney disease (CKD), a disease state in which a patient experiences little to no kidney
function. One role of healthy kidneys is to filter blood and remove excess fluid and metabolic
waste from the body, and with inadequate kidney function, that ability is impaired.39 Without
working kidneys, excess fluid, waste, minerals, and metabolites are poorly excreted through
urine, influencing accumulation in the body.39
Metabolite and fluid accumulation leads patients with ESRD to require intensive medical
care, including dialysis treatments to filter the patient’s blood in absence of adequate kidney
function.1 Two primary variations of dialysis treatment include peritoneal dialysis, and
hemodialysis (HD), with HD being the most frequently selected treatment.39,40 In the US, HD is
typically a four-hour treatment that patients receive in a specialized facility, three times weekly.39
HD serves to remove the excess substances built up in the patient’s body that would have
otherwise been excreted as urine under normal circumstances.39 During the time between dialysis
sessions, also known as the interdialytic period, excess minerals and organic metabolites
accumulate in the body, which can cause disturbances in the body’s fluid status. Within HD
patients, expansion of blood volume, and large interdialytic fluctuations of total fluid volume
between HD treatments can increase or exacerbate health risks including cardiovascular diseases
(CVD) such as hypertension (HTN).7 With upwards of 80-90% of HD patients experiencing
HTN8, and CVD being the main cause of death among ESRD patients encompassing 41% of
patient deaths10, prevention and treatment strategies are needed to overcome the HTN and CVD

18

risks HD patients face. Common approaches to alleviate the negative health impacts of HTN in
the HD population include various lifestyle changes and pharmaceutical approaches.
LITERATURE REVIEW
The Traditional Renal Diet
High mortality rates secondary to CVD within the HD population are concerning and
dietary approaches are often recommended for HTN and CVD risk control. Interdialytic blood
metabolite accumulation is a hallmark of the disease, upsetting fluid balance in the body.
Traditionally, renal diet recommendations promote dietary mineral restrictions in hopes of
preventing irregular blood mineral concentrations and fluid shifts. These traditional renal diet
guidelines are quite restrictive, with limitations focused on sodium, potassium, and phosphorus
intake for HD patients.3
Dietary Sodium
In terms of HTN and CVD, a primary nutrient of concern is sodium. Sodium is a mineral
and electrolyte important for fluid regulation and blood pressure (BP). Sodium is the principle
extracellular cation, and is a strong moderator of water absorption and retention, with high
sodium levels correlated to water retention.41 For HD patients unable to excrete excess fluid
waste appropriately, any consumed sodium and in turn retained water will increase blood
volume.41 This increase in blood volume then elevates BP, leading to development or
exacerbation of HTN. In addition to sodium’s strong ability to retain water, it also plays a role in
thirst. Thirst for fluids is a physiological stimulus that can be increased if the body contains
excess sodium levels.6 This stimulus is so strong, asking an individual to limit their fluid intake
without instructing them on sodium limitations has even been considered inhumane.6 Because
HD patients are limited in their fluid waste excretion, any additional fluid intake will impact their
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blood volume, and can lead to cardiovascular (CV) concerns including HTN and aortic stiffness7,
supporting the need to restrain thirst. Because sodium causes the body to retain water, and
increases an individual’s thirst and drive to consume liquids, high sodium intake can drastically
alter blood volume and pressure.41 In an investigation with greater than 30,000 individual HD
patients, large gains of body fluid between dialysis sessions, more than 4.0 kg, were correlated
with higher risk of death over the two years following9, indicating the need for interventions.
HTN rates are so elevated, effecting an estimated 80-90% of HD patients8, and CVD risk is
rampant for HD patients. As blood volume overload (VO) is predicted as one of the most
frequent components of HTN progression27, there is a strong argument for sodium restriction
within this population.
Based on this concept, adjusting sodium intake has been investigated as a treatment for
fluid retention and HTN within the HD population. A study by Maduell and Navarro17, attempted
to reduce dietary sodium intake in HD patients. Decreasing sodium intake led to significant
reductions in patient’s systolic and diastolic BP. From this 15-subject study, researchers found
sodium limitations to be an important controller of HTN in HD patients, and found sodium
restrictions to be more effective than antihypertensive medications for lowering BP.17
Although sodium restrictions could be a strong determinant of fluid balance and HTN in
HD patients, there are challenges to decreasing sodium intake. Sodium is used as a preservative
for many processed food products and is highly abundant in restaurant foods as well.32As most
foods are naturally low in sodium, foods that have been modified or processed prior to
consumption are the most common source of sodium in the American diet. With an abundance of
sodium available for US consumers, most Americans meet and exceed daily recommended
sodium intake for adults.32 Increased access and intake of sodium rich foods creates concern in
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regards to elevated body fluid levels, and CVD risk for HD patients is greatly increased with
excess sodium intake. Elevated body fluid poses a serious CV threat to HD patients, and due to
sodium’s strong correlation with overall fluid retention, considerations should be make regarding
sodium intake for HD patients.
Dietary Potassium
Another nutrient of concern that can accumulate in the blood between HD sessions is
potassium. Traditional renal diet recommendations include guidelines for potassium intake to
discourage accretion of potassium in the blood.39 Hyperkalemia, excess blood potassium, is the
most common metabolite abnormality for HD patients.42 Hyperkalemia is associated with higher
risk of CV mortality for HD patients43, making alterations in dietary potassium and other medical
treatments a focus for HD patients to achieve optimal blood potassium levels.
Dietary potassium limitations are traditionally recommended for HD patients to support
potassium balance and decrease hyperkalemia risk. However, strict potassium limits can pose
concerns for various food groups due to the high potassium concentration in many nutrient rich
foods. Some foods that are naturally high in potassium include fruits, vegetables, nuts, and
legumes, foods that are also notably high in fiber and beneficial nutrients.44 Potassium is also
used as an additive to many products including soft drinks and bread, illustrating how difficult
avoiding dietary potassium can be.45 Decreasing hyperkalemia risk is still essential to reducing
CVD risk, but restriction of all potassium foods may not be necessary. Data linking naturally
potassium rich foods to adverse health outcomes is limited.43 Furthermore, foods with potassium
added for preservative or flavor purposes often have low nutrient density and are not typically
favorable selections.20 With limited research discussing the benefits and downsides of natural
potassium in nutrient rich foods, these recommended limits may be unnecessarily strict.
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Additionally, as foods with added potassium are often nutrient poor, these foods should likely be
the initial target when removing potassium containing foods from the diet. Continuing research is
pursuing investigation of what quantity of natural and added potassium is safe for HD patients.20
Although a patient may require potassium intake limitations, restricted consumption of foods
naturally containing potassium may be less necessary than previously indicated.20 With limited
data supporting dietary potassium restrictions, fresh produce and other natural potassium
containing foods may still be safe for HD patients. Further evidence is needed to determine
appropriate potassium recommendations for HD patients.
Dietary Phosphorus
Phosphorus, similar to potassium, is another mineral causing concern for HD patients
with the potential of hyperphosphatemia, or high blood phosphorus46, due to patient’s limited
excretion of phosphorus through urine. Limitations on all dietary phosphorus are traditionally
noted as a preventative method for HD patients to avoid hyperphosphatemia, but recently, this
ideology is being challenged.47
Foods that are naturally high in phosphorus include milk, cheese, beans, and meat42, with
other foods such as carbonated sodas and processed foods being high in phosphorus from
additives and preservatives.32 Research indicates that inorganic phosphorus added to foods
during processing has up to 100% absorption rates within the gut, in comparison to the 40-60%
of natural phosphorus that is absorbed from unprocessed foods.47 Although absorption rates
differ, dietary recommendations do not decipher between naturally phosphorus rich foods and
those with added phosphorus from processing.47 Furthermore, natural phosphorus is often present
in foods with higher levels of protein and/or fiber, indicating extensive dietary phosphorus
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limitations may be harmful to an individual’s ability to consume adequate protein47, a consistent
concern for this population.36
In efforts to avoid hyperphosphatemia, while maintaining adequate protein and energy
intake, avoidance of phosphorus additives and processed foods is indicated, without limitation on
natural phosphorus and protein rich foods.47 This method will allow patients greater food variety
and could improve patient protein intake, common HD patient concerns.14 Additionally, patients
may have improved health outcomes as more restrictive phosphorus recommendations have been
associated with higher mortality rates among HD patients.46 With research indicating differences
between added and naturally occurring phosphorus, patients may be able to avoid
hyperphosphatemia by eating foods such as meats, beans, and dairy, while actively avoiding
added phosphorus within processed foods.
Traditional Renal Diet Challenges
The traditional renal diet has been described as one of the most challenging diets a
dietitian can prescribe to patients11, including limitations on sodium, potassium, and phosphorus.
Unfortunately, this restrictive diet produces limited health outcomes in terms of HTN and CVD.
Previous studies have investigated guidelines for limiting mineral consumption for HD patients,
often noting foods such as beans, root vegetables, and fruits as high in unhealthy minerals.44 In
addition to the general challenge of attempting to understand and achieve these strict dietary
goals, further barriers are seen in terms of processed foods. Many patients are not educated on
levels of minerals present in highly processed food items, with process foods being defined as
those items that have been deliberately changed in some way from the time of origin to the time
of consumption.48 Processed foods may not be on the exclusion list traditionally given to HD
patients, but these foods likely contain unhealthy amounts of minerals.32 Additionally, processed
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foods are more often insufficient in fiber and essential nutrients, components HD patients
traditionally lack within their diet, while still containing astonishingly high amounts of sodium.12
Traditional renal diet guidelines are currently limiting patient food options, while being unclear
about the use of processed foods and the sodium content that may be hiding within these
products.32,49 With the expansive presence of processed foods and mineral additives used for
flavor and preservation, identifying and avoiding foods high in sodium, potassium, and
phosphorus can be difficult.32,44
With traditional renal dietary limitations in place, HD patients are also particularly prone
to suffering from protein-energy wasting11, including multiple nutritional and catabolic
alterations that occur alongside kidney disease and failure.36 By reevaluating these past
guidelines, a patient may be able to improve their nutrition status with liberation of phosphorus
intake and inclusion of the previously limited dairy and meat food groups.47 Moreover, guideline
reconsideration may improve the vitamin and mineral deficiencies HD patients typically
display11,50 with more freedom regarding fruit and vegetable intake, previously limited due to
high potassium concentration.14,44 With indication that naturally-occurring potassium and
phosphorus rich foods may be safe for patients to consume, some guidelines of the traditional
renal diet may be less necessary than previously thought.
Additionally, the complex guidelines of the traditional renal diet may detract attention
from the sodium limitations patients likely need to focus on to improve their HTN and CV risk.
Extensive dietary guidelines can incur poor dietary adherence based on a patient’s ability and
desire to pursue behavior changes. This includes patient differentiation in terms of cognitive
abilities, cultural norms, and perception of potential health outcomes.51 When delving further into
this issue, difficulties with social support, inadequate guidance offered to the patient by a health
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care provider, and limited patient understanding of disease state increasingly limits dietary
adherence.13,14 As these guidelines are extensively complicated, some patients are unable to
comprehend the information necessary for success. Also, patients who are unable or unwilling to
adhere to dietary recommendations will not achieve highly on this restricted diet.13,14 HTN and
excessive fluid retention are discussed in many research articles and the use of dietary sodium
restriction is often noted.5,15,17 These articles strongly advocate for limitations in dietary sodium,
but provide little information as to how the process of moving towards a low sodium diet may
work. Additionally, they lack documentation as to the potential change in BP and antihypertensive medications that may ensue should an individual limit their sodium intake. Though
potentially applicable to American HD patients, most related research is conducted outside of the
US. There is a possibility for the positive sodium restricted diet outcomes seen in Italy, Turkey,
and France7,15,16 to also take place within the US, but further research is needed to confirm.
Research is also needed to investigate the process of limiting sodium and the related outcomes,
which will be relevant in future research for patients and practitioners to understand sodium
restriction benefits for HD patients.
The challenges identified with the traditional renal diet make it difficult to pursue, and
the identified weakness of its recommendations truly contest the necessity of this diet. In efforts
to create a diet that patients can understand and achieve when they are ready for behavioral
modifications, further investigation is warranted to determine meaningful and attainable dietary
recommendations for HD patients.

25

Anti-Hypertensive Medications
As discussed previously, BP control is crucial for HD patients to maintain their CV
health due to their limited liquid waste excretion and blood metabolite build up. In addition to
diet or lifestyle changes, pharmaceutical treatment approaches are an option to achieve
recommended BP levels.
Anti-hypertensive medications are identified as the most common method of treatment
for HD patients with HTN5, with multiple types of anti-hypertensive medications being
prescribed individually or in tandem.27 With many classes of medications available, patients can
receive multiple prescriptions with varying outcomes depending on their CV health,
comorbidities, and physician. In general, the US is one of the highest users of anti-hypertensive
agents.52 Poly-pharmaceutical therapies are so common, that amongst a group of 205 American
HD patients taking antihypertensive medications, 58% of those individuals were taking two or
more medications daily.18
With a poly-pharmaceutical approach in place, improved BP outcomes would be
expected, but medication based therapies often have limited effects on BP. In a study of 2535
HD patients prescribed one or more anti-hypertensive medications, 55-75% of patients remained
hypertensive above 140 mmHg for their systolic BP.27 Limited outcomes for BP management
may be related to the varying etiologies of HTN, as patients with HTN unrelated to blood VO
seem to fair better to the treatment, as opposed to those individuals who have excessive blood
volume impacting their BP.27 As many HD patients have VO contributing to their HTN, the
likelihood of success with anti-hypertensive medications is limited. It is likely that a treatment
reducing total blood VO will have greater impact on HD patient BP than altering other targets.27
In addition to inadequate BP reduction outcomes, pharmaceutical approaches have challenges
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including cost, side effects, and initiation and maintenance of medication routines. For patients,
unfamiliar or unable to access affordable medication options, adherence and maintenance to the
medication regimen may be difficult. Furthermore, some patients challenged with handling their
own care including continuous medication usage can increase concern for misuse or poor
medication adherence due to limited ability to care for themselves and maintain medications.5,15,18
Although medications are a commonly prescribed approach for HTN reduction, the outcomes are
limited and use is challenging for numerous HD patients, indicating need for further HTN
treatment consideration.
Ultrafiltration Techniques
The process of HD is an ultrafiltration (UF) of a patient’s blood to remove excess waste
and fluids retained between dialysis sessions. Traditional US HD processes are successful in
removing some excess fluid and metabolites from the blood based on a patient’s estimated dry
weight (EDW). The EDW is predicted at each dialysis session by a nephrologist, and is based on
the practitioner’s best approximation of a patient’s weight if they did not have any excess fluid
retention.9,21 Although these estimations can be close, the ability for the practitioner to accurately
predict every patient’s EDW, every session, is unlikely. Even with substantial levels of human
error, limited options for predictive methods have led to EDW being the standard approach for
nephrologists writing UF prescriptions.9 Although traditional HD approaches for American
patients use EDW quite consistently39, some researchers have discussed altering UF approaches
to improve BP and VO outcomes. Many of the most successful approaches to decreasing HTN in
HD patients includes using extended or more frequent HD sessions, allowing for greater fluid
removal and blood volume management.27Another investigation looked at providing four-hour
HD sessions removing as much fluid as the patient could safely tolerate, with additional HD
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sessions as indicated for elevated blood volume and BP.21 This approach did not utilize EDW to
determine the UF prescription, but instead used UF to consistently decrease BP without causing
severe instances of hypotension or other contraindications to fluid removal.21 Through this
technique more fluid was removed allowing patients to come closer to a status of little to no fluid
retention. With this personalized approach to the UF protocol, patients in this study saw
decreases in cardiac volume, and BP control was more easily achieved, leading researchers to
expect improved CV outcomes.21 Further reinforcement for individualized approaches to HD
treatments are recommended due to the fine precision available through HD technology currently
used at HD clinics. With the ability to create unique HD prescriptions based on a patient’s
individual needs at the time of their session, opportunities for improving BP and fluid balance
are available.53 Unfortunately, many HD clinics note difficulties regarding cost and staff training
levels as reasons to not pursue unique and adaptive HD prescriptions.53 With variations of UF
treatments indicating potential improvements for BP and CVD risk, HD patients with HTN may
be good candidates for alterations in the UF prescription as achievable to provide improved
health outcomes.
Comparing Hypertension Management Techniques
Due to the high prevalence of HTN and CVD in HD patients, determining appropriate
treatment approaches is vital to patient health outcomes. With distinct differences between
dietary changes, pharmaceutical approaches, and UF techniques, pinpointing the best treatment
plan can be puzzling. Some HD clinics are making transitions in their daily patient care in efforts
to reduce BP.
Conversion from a medication based therapy for HTN to sodium restriction and UF
therapy has taken place overseas in countries such as France. In a comparison of two respected
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European HD centers, a French clinic had distinguished differences in survival rates and BP.15
Investigating the mortality among patients at these clinics, the survival rate is markedly higher at
the French HD center, hypothesized to be related to the low prevalence of HTN among the
patients. The French clinic functions on a reduced sodium diet approach for BP regulation
accompanied by extended eight hour HD sessions to decrease blood VO. The English clinic
recommends a medication based approach for HTN with traditional four hour HD treatments,
similar to that of the US. With superior life expectancy outcomes for the French patients
provided low sodium diet recommendations and altered HD treatments, this research may call for
reevaluation of a medication based approach. In this case, sodium restriction and UF changes in
the French clinic seemed to decrease HTN as well as mortality rate, whereas anti-hypertensive
medications seemed to make less impactful differences, if any at all.15 For comparison to the US,
total sodium intake for the patients at the French clinic was about 1700 milligrams per day15,
with American patients consuming an average of 4200 milligrams of sodium daily54, indicating
opportunity for sodium intake improvements. This study’s findings are not alone, as similar
outcomes are seen in Turkish HD centers.
In a comparison between Turkish and American dialysis patients, individuals were
evaluated for HTN as well as mortality rates. For hypertensive US HD patients, medications are
often the primary treatment, alongside recommendations for the traditional renal diet. However,
Turkish patients follow approaches to reduce over hydration with more aggressive fluid removal
during HD, as well as a strict dietary sodium restriction without the potassium and phosphorus
limitations of the traditional renal diet. The combination of aggressive fluid removal during
dialysis and focusing dietary recommendations solely on sodium intake appears to improve BP
in most Turkish patients. With a 50% lower mortality rate among Turkish patients, it is likely
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that Turkish approaches to blood VO and sodium limitations are more effective than those used
in the US.55
One of the few comparison studies, Kayikciogly et al.16, tracked hypertensive HD patients at
two separate dialysis clinics treated with either a low sodium diet or anti-hypertensive
medications and compared BP outcomes. The 423 HD patients involved in this Turkish study all
received the same HD treatment approach. Individuals at Center A were actively recommended a
2000 milligram sodium diet daily for HTN, rather than being passively recommended a reduced
sodium diet and relying on anti-hypertensive medications provided at Center B. At Center A,
dietary sodium restriction indicated less strain on patient’s left heart ventricle indicating better
function, lower risk of hypotension following HD treatments, and improved systolic and diastolic
function. Additionally, patients adhering to a sodium restricted diet experienced lower
interdialytic weight gain (IDWG) between dialysis sessions than those only taking antihypertensive medication16, and notably lower IDWG is associated with greater survival rates.9
Following the conclusion of this trial, the positive CV outcomes indicate the therapy from Center
A, using sodium restriction, was more beneficial.9
Further investigations to decrease total blood volume and fluid retention with sodium
limitations had similar findings. Within a study of 15 HD patients, a dietary sodium limitation
was an important controller of HTN. These individuals experienced decreases in both systolic
and diastolic BP through the dietary sodium restriction, and the dietary lifestyle approach was
considered more effective than medication use, though no medications were compared within
this study.17 An additional case discussing sodium restriction and BP regulation for HD patients,
used an intervention approach to decrease dietary sodium intake from an average of 4.1 grams of
sodium per day to 2.8 grams of sodium per day. This intervention aided in significantly reducing
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patient systolic BP54, further supporting this platform. This strong viewpoint contradicts the
current popularity of anti-hypertensive drugs for HD patients.5 But although the transition from
medication based treatments to dietary approaches may seem beneficial, barriers to transitioning
from a pharmaceutical approach to a low sodium diet are still impacting patient success.
Dietary Sodium Reduction Challenges
Regardless of the strong research supporting use of a low sodium diet for BP control in
HD patients, there are continued personal and cultural barriers to this lifestyle. Studies often note
the challenges of following a sodium restricted diet including; inadequate access to low sodium
foods, lack of self-motivation or family support, varying dietary beliefs, personal attitudes, and
poor taste acceptance.13,31 With patients experiencing universal barriers to lifestyle changes as
well as those unique to them as an individual, finding approaches to overcoming these obstacles
is vital to patient success. Recent literature has considered ways to improve patient adherence,
with a large focus on increasing accessibility to lower sodium foods for patients following this
diet.
Sodium is often used in food processing as a preservative or to improve food taste.32
Foods naturally contain relatively low amounts of sodium, but approximately 75% of American
sodium intake comes from sodium added during processing.32 In efforts to control sodium
additions in processed foods, one study experimented with minimizing the sodium content of
common foods.56 Researchers decreased sodium additions by an estimated 50% in almost all
food categories and indicated that this would result in a 38% decrease of daily dietary sodium
intake for most individuals.56 Similarly, guidelines for maximum values of sodium additions are
being considered in efforts to decrease sodium consumption in America.49 These guidelines
would limit processing companies’ ability to exceed the maximum sodium amount designated,
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and may decrease individual’s daily sodium intake.49 It appears there is a great possibility to
change within the food industry that may benefit the sodium restrictions needed by HD patients.
Some concerns that may arise from the low sodium diet approach have been noted by
researchers, including risk of undernutrition. Some studies indicate that individuals may not
receive adequate amounts of micro and macro nutrients while on a limited sodium diet.11
Although it can be challenging to find some low sodium food alternatives, it appears that patients
can adequately achieve energy and protein intake with appropriate alternative food selections.11,57
Additionally, considering the other option of the restrictive traditional renal diet, the low sodium
diet approach will likely provide more nutrients than the alternative. Further success on the low
sodium diet can be found with maintenance of protein intake, as that indicates increased survival
rates.11 With consideration for nutrients at risk while on a sodium restricted diet, patients can
improve their HTN by consuming an adequate diet, specifically rich in protein and fulfilling
energy needs.
By using low sodium and minimally processed products, an individual can successfully
lower their sodium intake, which can decrease BP, while still maintaining health. This sodium
limitation approach is not always easy to follow, but may be a more successful alternative
therapy to anti-hypertensive medications.
Reconsidering HTN Treatment in the US
Research regarding sodium restriction for decreasing HTN among HD patients is not
unheard of, but it appears the US is struggling to include that concept into practice. Medications
are the most common treatment for HTN within the US. Unfortunately, with medication usage,
the effects on BP within this population seem to be limited, with less than half of patients able to
regaining control of their BP.58 Not only is this approach minimally effective for patients, but it
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may dissuade the introduction of a dietary approach that could have more effective outcomes. If
US HD clinics start to approach HTN treatments with a dietary sodium limitation, patients may
be able to experience outcomes similar to those in France and Turkey, with lower BP as well as
decreased left ventricular stress and reduced patient mortality rates.15,16,54,55 Additional
opportunity for improvements may be seeded within the UF protocol and prescriptions provided
to HD patients, allowing for greater individualization opportunities.9,21,58
Recent research developments challenge the details of the traditional renal diet, as well as
support dietary sodium changes versus medication based HTN management. Based on current
research, reconsideration of these guidelines should focus on diet achievability and patient needs,
while being conscious of minerals and providing adequate nutrients.11,20 These proposed dietary
recommendations would include limiting foods high in sodium additives such as processed or
restaurant foods. Additionally, this diet would allow more freedom for foods that are naturally
rich in potassium and phosphorus. By focusing a patient’s energy on reducing sodium instead of
the traditional renal diet, a patient will have greater food selections and may increase their ability
to find success achieving dietary changes. With the reconsideration of the traditional renal diet
and stronger focus on dietary sodium reduction, patients may experience positive CV health
outcomes, and decreases in systolic and diastolic BP, potentially even enough to warrant reduced
anti-hypertensive medication use. Utilization of this low sodium focus may be further improved
through individualized UF protocol, focused on improving a patient’s VO and BP status, rather
than on EDW. As investigations are limited regarding this low sodium diet focus and unique UF
prescriptions within the US, further research should be considered to allow HD patients
opportunities to achieve the beneficial health outcomes seen through low sodium diet and
individual UF approaches in other countries.
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Table 1. Baseline Patient Characteristics
Demographics and Clinical Data

Participants (n=23)

Age in years (standard deviation)

55.7 (13.3)

Male (%)

12(52.2)

Hispanic (%)

1(4.5)

African American (%)

9 (40.9)

Patients w/ Diabetes (%)

10 (45.5)

Avg. Weight in kg (standard deviation)

93.6 (±24.4)

Avg. IDWG in kg (standard deviation)

3.15 (±1.1)
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Table 2. Body Fluid Levels
Bioimpedance

Pre-Intervention

Post-Intervention

p-value

Total Body Water in Liters

45.8 (±10.8)

44.3 (±8.8)

0.10

Total Body Water %

49.8 (±7.1)

49.4 (±6.4)

0.61

Spectroscopy Data

All values presented are mean (standard deviation). n=23
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Table 3. Blood Pressure and Medication Outcomes
Blood Pressure Data

Pre-Intervention

Post-Intervention

p-value

Systolic BP in mmHg

160 (±25)

156 (±23)

0.56

Diastolic BP in mmHg

81 (±20)

79 (±15)

0.73

3 (±1)

2 (±1)

0.003

# BP Medications

All values presented are mean (standard deviation). n=23
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Table 4. Dietary Intake Evaluation
Dietary Intake Data

Pre-Intervention Post-Intervention

p-value

Energy Intake in kcals

1588 (±1061)

1366 (±455)

0.38

Protein Intake in grams

61 (±30)

56 (±21)

0.60

Protein Intake in g/kcal

0.72 (±0.50)

0.65 (±0.28)

0.79

Sodium Intake in mg

2886 (±1570)

2315 (±1095)

0.13

Sodium Intake in mg/kcal

1.96 (±0.84)

1.69 (±0.53)

0.16

All values presented are mean (standard deviation). n=23
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Table 5. Dietary Knowledge Evaluation
Dietary Knowledge

Pre-Intervention

Post-Intervention

p-value

Protein Knowledge % Correct

81 (±18)

84 (±14)

0.25

Phosphorus Knowledge % Correct

66 (±15)

74 (±14)

0.04

Sodium Knowledge % Correct

68 (±27)

76 (±30)

0.06

All values presented are mean (standard deviation). n=23
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Figure 1. Reduction in Liters of Volume Overload Following Intervention.

30

p-value = 0.004

25

Volume (L)

20
15
p-value = 0.01

10
5
0
Extracellular Fluid

Volume Overload

-5
Pre-Intervention

Post-Intervention

All values presented are mean (+ standard deviation)

47

Figure 2. Significant Post-Intervention Improvement in Volume Overload Percentage.
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APPENDIX A: 24-HOUR RECALL FORM
Researcher: __________

Pt ID: __________

Date Consumed: _________________

Meal

Time

Date Recorded: _________________

Food/Drink
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Portion/Brand

Location

APPENDIX B: PATIENT SUMMARY SHEET
Pt ID: _____

Goal Setting:
Initial Date

Goal (SMART)

Aim Achievement Date

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Date: ____/____/_______

Current Habits:
Positive Habit

Strategies for Maintaining Habit

Concerning Habit

Strategies for Improving Habit
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Pt ID: ___________

APPENDIX C: GOALS TEMPLATE
Current Date: ___________ Researcher: ______________

Current Goal #1
Initial Set Date: ____/____/________
Goal:

Actual Achievement Date: ____/____/________
Are all SMART components met? (yes/no)
- Specific: ______________________
- Measurable: __________________
- Attainable: ______________
- Relevant: ______________________
- Time Related: _______________

Aim Achievement Date:
____/____/________
Did the patient achieve this goal? How did they achieve it, or why did they not achieve it?
____________________________________________________________________________
____________________________________________________________________________
__________________________________________
If the goal was not achieved, restructure the goal to the SMART model and patient
needs:
- Was it specific enough to achieve?
- Can you specify the measurement to be numerical/unit based rather than more/less?
- Can this patient achieve this action within the specific time period?
- Is there a clear time frame?
- Utilize the goal builder section to improve this goal for better achievement
If the goal was achieved:
- Use the goal builder section to develop this goal even further for the patient
- Use the goal builder section to create a new goal in an area that has not yet been
approached by this patient
- Use successful approaches of the last goal to fuel the new goal

Goal Builder #1:
Current Date: ____/____/________
Goal:

Aim Achievement Date: ____/____/________
Are all SMART components met? (yes/no)
- Specific: ______________________
- Measurable: __________________
- Attainable: ______________
- Relevant: ______________________
- Time Related: ________________

Additional notes or sub-goals for success:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
________________________________________
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